© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
enVVeno Medical Corporation (NVNO) stock surged +0.18%, trading at $11.12 on NASDAQ, up from the previous close of $11.10. The stock opened at $11.38, fluctuating between $11.12 and $11.68 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | 11.38 | 11.68 | 11.10 | 11.12 | 60.93K |
| Sep 09, 2026 | 11.41 | 11.82 | 10.85 | 11.10 | 94.42K |
| Sep 08, 2026 | 11.31 | 11.62 | 11.16 | 11.49 | 4.18K |
| Sep 04, 2026 | 11.05 | 11.44 | 11.05 | 11.44 | 2.11K |
| Sep 03, 2026 | 11.42 | 11.42 | 11.00 | 11.10 | 2.42K |
| Sep 02, 2026 | 11.44 | 11.55 | 11.21 | 11.30 | 4.77K |
| Sep 01, 2026 | 11.36 | 11.36 | 10.53 | 10.98 | 42.2K |
| Aug 31, 2026 | 10.51 | 11.47 | 10.26 | 11.47 | 24.94K |
| Aug 28, 2026 | 10.80 | 10.80 | 10.67 | 10.75 | 3.19K |
| Aug 27, 2026 | 11.53 | 11.94 | 11.20 | 11.24 | 6.87K |
| Aug 26, 2026 | 11.30 | 11.95 | 10.81 | 11.47 | 17.3K |
| Aug 25, 2026 | 10.70 | 11.17 | 10.34 | 10.80 | 3.88K |
| Aug 24, 2026 | 10.59 | 11.41 | 10.30 | 10.35 | 20.35K |
| Aug 21, 2026 | 10.78 | 11.15 | 10.13 | 10.29 | 21.2K |
| Aug 20, 2026 | 10.44 | 11.59 | 10.17 | 10.39 | 26.95K |
| Aug 19, 2026 | 11.25 | 11.25 | 10.48 | 10.48 | 28.53K |
| Aug 18, 2026 | 12.00 | 12.49 | 10.73 | 11.04 | 25.13K |
| Aug 17, 2026 | 11.09 | 12.31 | 10.15 | 11.80 | 7.79K |
| Aug 14, 2026 | 10.80 | 10.99 | 10.71 | 10.99 | 1.44K |
| Aug 13, 2026 | 10.86 | 10.86 | 10.86 | 10.86 | 646 |
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
| Employees | 33 |
| Beta | 1.05 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |